Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E S Daar

Showing results (51-60 of 53) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 53 results.
Journal of Neurovirology|April 4, 2014
Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CARTJ Harezlak, R Cohen, A Gongvatana, et al.
JAMA|September 29, 1999
Reduced antiretroviral drug susceptibility among patients with primary HIV infectionS J Little, E S Daar, R T D'Aquila, et al.
HIV Medicine|August 14, 2018
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trialsD Hagins, C Orkin, E S Daar, et al.
Pageof 6

Showing results (51-60 of 53) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 53 results.
Journal of Neurovirology|April 4, 2014
Predictors of CNS injury as measured by proton magnetic resonance spectroscopy in the setting of chronic HIV infection and CARTJ Harezlak, R Cohen, A Gongvatana, et al.
JAMA|September 29, 1999
Reduced antiretroviral drug susceptibility among patients with primary HIV infectionS J Little, E S Daar, R T D'Aquila, et al.
HIV Medicine|August 14, 2018
Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trialsD Hagins, C Orkin, E S Daar, et al.
Pageof 6